Literature DB >> 17206680

Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations.

Ioannis E Koutroubakis, Konstantinos Karmiris, Leonidas Bourikas, Elias A Kouroumalis, Ioannis Drygiannakis, Dimitrios Drygiannakis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206680     DOI: 10.1002/ibd.20038

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  5 in total

1.  Prevalence of IgA class antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease (IBD).

Authors:  Hans-Jacob Haga; Oyvind Palm; Elisabeth Peen
Journal:  Clin Rheumatol       Date:  2011-02-22       Impact factor: 2.980

2.  Spondyloarthropathies in autoimmune diseases and vice versa.

Authors:  Oscar M Pérez-Fernández; Rubén D Mantilla; Paola Cruz-Tapias; Alberto Rodriguez-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2012-02-15

3.  Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity.

Authors:  Afshin Shafaghi; Fariborz Mansour-Ghanaei; Maryam Rostamnejad; Alireza Amir Maafi; Asghar Haji-Abbasi; Hossein Froutan
Journal:  Med J Islam Repub Iran       Date:  2014-07-22

4.  Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohn's Disease.

Authors:  Koen M J Janssen; Hilde Hop; Arjan Vissink; Gerard Dijkstra; Menke J de Smit; Elisabeth Brouwer; Johanna Westra
Journal:  Int J Environ Res Public Health       Date:  2020-11-01       Impact factor: 3.390

5.  Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study.

Authors:  Koen M J Janssen; Menke J de Smit; Elisabeth Brouwer; Fenne A C de Kok; Jan Kraan; Josje Altenburg; Marije K Verheul; Leendert A Trouw; Arie Jan van Winkelhoff; Arjan Vissink; Johanna Westra
Journal:  Arthritis Res Ther       Date:  2015-07-09       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.